Royalty Pharma plc Annual Net Income (Loss) Attributable to Parent in USD from 2018 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Royalty Pharma plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2018 to 2024.
  • Royalty Pharma plc Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was $208M, a 57.9% decline year-over-year.
  • Royalty Pharma plc Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was $859M, a 24.3% decline year-over-year.
  • Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2024 was $859M, a 24.3% decline from 2023.
  • Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2023 was $1.13B, a 2550% increase from 2022.
  • Royalty Pharma plc annual Net Income (Loss) Attributable to Parent for 2022 was $42.8M, a 93.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.